Method for evaluating the ability of a composition to prevent muscle damage and fatigue; food supplement and drug

Abstract

Disclosed is a method for evaluating the ability of a chemical substance or a chemical composition to prevent muscle fatigue and damage induced by physical exertion in humans by comparing the effect the chemical substance or a chemical composition has on a combination of three biological markers in cultured human primary skeletal muscle cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. Ser. No. 16 / 097,416 filed Oct. 29, 2018, which is a National Stage Entry of International Patent Application No. PCT / FR2017 / 050508 filed Mar. 8, 2017, which claims priority to FR Application No. 1653737 filed Apr. 27, 2016. Each of the previously noted applications is hereby incorporated by reference in their entirety.BACKGROUND OF THE INVENTION[0002]The invention relates to an in vitro method of tests aimed at selecting a chemical substance or a chemical composition intended to prevent and / or reduce muscle fatigue and muscle damage induced by physical exertion in human beings.[0003]The subject of the present invention is also abovementioned chemical compositions and food supplements, and medicaments comprising same.[0004]Any period of intense or prolonged muscle activity can cause, in human beings, a decrease in muscle performance considered to be muscle weakness. Muscle weakness can involve all t...

AI Technical Summary

Benefits of technology

This patent describes a method for preventing muscle fatigue and damage caused by physical exertion. The method involves selecting a substance or composition that can be used as a nutritional supplement or in food to prevent these conditions. The method also involves using a ratio to determine if the substance or composition is effective in preventing muscle fatigue and damage. The invention also includes a food supplement composition that provides a concentrated source of nutrients to prevent deficiencies or meet specific needs during physical exertion. The method can be used for therapy to prevent muscle fatigue and damage.

Problems solved by technology

Any period of intense or prolonged muscle activity can cause, in human beings, a decrease in muscle performance considered to be muscle weakness.

On the other hand, when muscle weakness is slow to reverse or difficult to reverse, and associated with structural changes in the muscle, it is considered to be exercise-induced muscle damage (EIMD).

Muscle damage causes an immediate weakness of the muscle which can last for several days before disappearing.

The production of hydronium ions induces a decrease in pH and the occurrence of muscle acidosis, which interferes with the muscle contraction mechanisms.

Serum lactate is the most well known muscle fatigue biological marker, since an increase in its content in the blood shows that aerobic ATP production is insufficient and needs to be supplemented with anaerobic production thereof.

Muscle damage induces a cascade of events resulting in immediate soreness or soreness delayed over time.

The development of effective chemical substances or chemical compositions for the prevention and treatment of the effects associated with muscle fatigue and with muscle damage requires a lengthy and expensive research process since it involves an iterative approach between the phases of preparing the substances or compositions and the phases of evaluating the biological performances of said substances or compositions.

Moreover, the methods of biological evaluation using models on animal cells, or involving animals, are less relevant since the metabolism of animals is different than that of human beings.

These methods are relevant for evaluating the efficacy of a product, but are not accessible for screening and for selecting several ingredients.

It appears that the prior art does not disclose an in vitro method for selecting a chemical substance or a chemical composition which makes it possible to concomitantly prevent muscle fatigue and muscle damage induced by physical exertion in human beings, which is capable of being usable in medium throughput in a screening approach, which does not involve animal cells, which is reproducible, sensitive, discriminating and efficient, and which is suitable for the human nutrition market.

More particularly, the prior art neither discloses nor teaches such methods of selection involving human primary skeleton muscle cells and comprising a step of stimulation by adding an ionophore agent.

Consequently, the absence of suitable and efficient in vitro test methods, which are capable of being suitable in medium throughput, hampers the development of efficient food products or foods which make it possible to concomitantly prevent muscle fatigue and muscle damage induced by physical exertion in human beings.

Images